Public Health Emergency of International Concern (PHEIC)
Polio this week as of 4 October 2017</strong [GPEI]
:: Summary of newly-reported viruses this week:
Syria: seven new circulating vaccine derived poliovirus 2 (cVDPV2) cases reported, five cases from Mayadeen and one case from Boukamal districts, Deir Ez-Zor governorate, and one case from Thawra district, Raqqa governorate. Three new cVDPV2 positives from healthy children, two from Mayadeen and one from Bokamal districts, Deir Ez-Zor governorate.
Pakistan: four new wild poliovirus 1 (WPV1) positive environmental samples, three reported in Sindh province, and one in Balochistan province.


Situation reports on the polio outbreak in Syria
Situation update 3 October 2017
:: Seven (7) new cases of cVDPV2 have been confirmed this week —5 cases from Mayadeen and 1 from Boukamal districts, Deir Ez-Zor governorate, and 1 case from Thawra district (newly infected), Raqqa governorate. Isolates from some cases had been laboratory pending for some time. The most recent case, a child from Boukamal with no history of polio vaccination, had onset of paralysis on 5 August.
:: The total number of cVDPV2 cases is 47.
:: Poliovirus has been isolated from stool samples collected from a healthy child in Damascus, as part of screening in place for IPDs from Deir Ez-Zor and Raqqa. The child, from Boukamal, Deir Ez-Zor, had samples collected on 19 August, the day of arrival. WHO and MoH will continue to take samples from healthy children in areas of Damascus with high numbers of IDPs, to ensure there is no wider circulation.
:: Preparation for the second immunization round for Raqqa is ongoing. Newly accessible villages in Thawra district have been included in campaign plans.
:: A series of meetings between partners to review outbreak response activities to date and to identify priorities for the next two months took place in Beirut 29-30 September.


WHO Grade 3 Emergencies  [to 7 October 2017]
The Syrian Arab Republic
:: Syria cVDPV2 outbreak situation report 16, 3 October 2017
[See Polio above for detail]

:: Field visits to Ibb and Hudaydah: Summary of immediate action points and recommendations, 20 September 2017  2 October 2017
[See Cholera above for more detail]

WHO Grade 2 Emergencies  [to 7 October 2017]
:: Situation Report 4 – 3 October 2017
 Key Highlights

  1. Current estimation of vulnerable people in Bangladesh: As of 28 September 2017, cumulative number of new arrivals in all sites of Ukiah, Teknaf, Cox’s Bazar and Ramu are 501 8001. This includes 448 100 in four upazilas of Cox’s Bazar district, 35 000 in registered camps for affected population and 18 700 in Naikhongchhari of Bandarbhan district. The total Rohingya population in Bangladesh is now estimated to be approximately 800 000.
  2. Status on the new site development: Site Development Task Force is collaborating with Office of the Refugee Relief and Repatriation Commission (RRRC) and army officials on road construction in Kutapalong extension site and development of the 2000 acre site plan. Construction will start once Master Plan is finalized and refining of zoning diagram drafted by RRRC is completed.
  3. Special vaccination campaign reaches its target: Vaccination campaign ended on 03 October with 135,519 receiving MR vaccines; 72,334 children receiving bOPV and 72,064 children receiving Vitamin A, since the campaign began on 16 September. WHO and partners are now ensuring that routine immunization activities are scaled-up in the makeshift and spontaneous settlements.
  4. 900,000 doses of oral cholera vaccines sanctioned: International Coordinating Group (ICG) on Vaccine Provision has released 900 000 doses of OCV from the global stockpile to prevent spread of cholera amongst recently arrived vulnerable populations and host communities in areas around Cox’s Bazar. The vaccines are anticipated to arrive in Bangladesh on 07 October.

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
:: Iraq: Humanitarian Bulletin, 16-30 September 2017 | Issued on 1 October [EN/AR/KU]

Syrian Arab Republic
:: 5 Oct 2017  Statement by Panos Moumtzis, the Regional Humanitarian Coordinator for the Syria Crisis on the recent escalation of violence in Syria [EN/AR]


UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
DRC  No new announcements identified
EthiopiaNo new announcements identified
Nigeria  No new announcements identified
Somalia  – No new announcements identified

Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

EBOLA/EVD  [to 7 October 2017]

HHS accelerates development of first Ebola vaccines and drugs
September 29, 2017
Actions under Project BioShield could protect health from bioterrorism, naturally occurring outbreaks
Hundreds of thousands of Americans could be protected from or treated for Ebola infections through the first purchase of vaccines and therapeutic drugs by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The vaccines and drugs are the first for Ebola to receive Project BioShield funding which supports late-stage development toward licensure and stockpile purchases.

“Today we are prepared to add four Ebola countermeasures to the stockpile whereas three years ago, very few products were even in early stages of development,” BARDA Director Rick Bright, Ph.D., said. “This marks a pivotal moment in U.S. and global preparedness for future public health emergencies from viral hemorrhagic fevers like Ebola. We reached this point at unprecedented speed, and that’s a direct result of innovative approaches to product development and to partnering across the U.S. government, other nations, and private industry.”…

Under the agreements announced today, BARDA will provide Project BioShield funding for each company to validate its manufacturing processes and undertake the final preparations necessary to apply for approval through the U.S. Food and Drug Administration (FDA). While that work is completed, BARDA can purchase the vaccines and drugs for potential use in a public health emergency.

BARDA could purchase up to 1.13 million regimens of vaccine, including a single-dose vaccine from Merck Sharp & Dohme Corp of Whitehouse Station, New Jersey, and a two-dose vaccine from Janssen Vaccines and Prevention B.V. of Leiden, The Netherlands. In addition, BARDA will purchase a therapeutic drug from Mapp Biopharmaceutical, Inc. of San Diego, California, and a therapeutic drug from Regeneron Pharmaceuticals, Inc. of Tarrytown, New York.

Merck Sharp & Dohme Corp’s single-shot vaccine would be used to protect people who are at high risk of exposure to Ebola. BARDA will provide $39.2 million for late stage development and purchase. The vaccine showed potential efficacy during testing in Guinea, West Africa, using a ring-vaccination protocol. This approach aims to stop the spread of a virus by vaccinating everyone a patient came in contact with and everyone who came in contact with the patient’s contacts…

Janssen Vaccines and Prevention B.V.’s vaccine is a two-dose vaccine regimen that would be used to prevent illness in people who have not been exposed to Ebola but could be, such as health care workers and the general public. The regimen requires an initial vaccine which is protective against Ebola, followed by a second vaccine that uses different technology and boosts the body’s immune response. This two-dose approach has progressed into multiple Phase 3 studies and demonstrated efficacy in animal models…